Loading...
Biora Therapeutics, Inc.
BIOR•NASDAQ
Healthcare
Biotechnology
$0.22
$0.00(0.00%)

Financial performance has remained strong, with revenue growing from $872000.00 in Q4 2023 to $32000.00 in Q3 2024. Gross profit continued to perform well, with margins at 100% in the latest quarter. Operating income reached -$16.23M in Q3 2024, holding a steady -50709% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$16.23M. Net income dropped to -$18.40M, keeping EPS at -$5.04. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan